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RESEARCH ARTICLE
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Abstract:
Background:
Predicting survival for patients with metastatic bone disease in the extremities (MBDex) is important for ensuring the implant will
outlive the patient. Hitherto, prediction models for these patients have been constructed using subjective assessments, mostly lacking
biochemical variables.
Objectives:
To develop a prediction model for survival after surgery due to MBDex using biochemical variables and externally validate the
model.
Methods:
We created  Bayesian  Belief  Network  models  to  estimate  likelihood  of  survival  1,  3,  6,  and  12  months  after  surgery  using  140
patients.  We  validated  the  models  using  the  data  of  130  other  patients  and  calculated  the  area  under  the  Receiver  Operator
Characteristic curve (ROC). Variables included: hemoglobin, neutrophil-count, C-reactive protein, alkaline phosphatase, primary
cancer, Karnofsky-score, ASA-score, visceral metastases, bone metastases, days from diagnose of primary cancer to index surgery
for MBDex, ischemic heart disease, diabetes, fracture/impending-fracture and age.
Results:
Survival probabilities were influenced by all biochemical variables. Validation showed ROC for the 1, 3, 6, and 12-months model:
68% (C.I.: 55%-80%), 69% (C.I.: 60%-78%), 81% (C.I.: 74%-87%) and 84% (C.I.: 77%-90%).
Conclusion:
Biochemical  markers  can  be  incorporated  into  a  prediction  model  for  survival  in  patients  having  surgery  for  MBDex  allowing
surgeons to offer more objective and individualized treatment options.
* Address correspondence to this author at the Department of Orthopedic Surgery, Musculoskeletal Tumor Section Rigshospitalet, University of
Copenhagen, Denmark; E-mail: Michala.skovlund@gmail.com
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1. INTRODUCTION
Successful treatment of metastatic bone disease in the extremities (MBDex) requires a multidisciplinary approach.
Most lesions may be treated in a non-surgical manner by incorporating radiation therapy, bisphosphonates, and pain
management  [1,  2].  However,  in  case  of  a  pathological  fracture  or  intractable  pain,  surgery  is  often  necessary  [3].
Various surgical implants such as internal fixation devices or joint replacement prostheses can be used, but each has
different indications, complication profiles and rehabilitation requirements. To determine which patients may benefit
from surgery, and, to determine whether a more durable implant may be necessary, surgeons need a tool that can help
predict each patient’s residual life expectancy.
The  definitive  surgical  strategy  is  often  considered  within  a  multidisciplinary  environment.  Factors  such  as
anatomical  location  of  the  metastatic  lesion,  information  regarding  the  primary  cancer  causing  the  lesion,  and  the
general health status of the patient influence surgical decision-making. However, the patient’s life expectancy is central
to choosing an effective surgical strategy.
Unfortunately, survival estimates made by health care professionals are inconsistent, at best. Most providers tend to
overestimate survival, which can lead to overtreatment, however, undertreatment is also a problem in these patients who
are terminal, but not necessarily terminally ill. A prognostic tool containing objective variables  is  therefore  necessary
[4 - 6].
Several risk factors for survival in patients having surgery due to MBDex have been identified [1, 2, 7 - 12] of what
many  variables  are  observer  depended  (e.g.  performance  status  or  surgeons  estimate  of  residual  life  expectancy).
Objective factors such as biochemical variables have been investigated in patients with metastatic bone disease, but
usually are employed as an “independent” predictor for survival, and as yet, have not been part of multivariate models
designed to estimate survival. Multivariate models containing hemoglobin, and absolute lymphocyte count—in addition
to a combination of objective and subjective information-are used to estimate the duration of survival and have been
externally validated [13, 14]. However, C-reactive protein [15, 16], alkaline phosphatase [17 - 21] and neutrophil count
[21 - 24] previously shown to be independent risk factors for survival have not yet been investigated in the context of a
multivariate model for survival prediction in MBDex patients.
With this in mind, we aim to investigate if a multivariate prediction model for survival after surgery due to MBDex
can be built using biochemical variables and furthermore; investigate how such model perform in an external validation.
2. MATERIAL AND METHODS
2.1. Study Design and Setting
This  study  obtained  ethical  approval  by  the  Danish  Health  Authorities  (ID-no:  3.3013-880/1)  and  Danish  Data
Protection  Agency  (ID-no:  30-1222).  Patients  were  identified  from  the  COpenhagen  BOne  Metastases  Database
(COBOM database [25]), which contains retrospectively collected clinical data from January 1st 2003 to 31st December
2013 of patients treated in our center for MBDex with joint replacement surgery or a diaphyseal spacer. Our center is
one of two tertiary referral centers for orthopedic oncology in Denmark and therefore the COBOM database can be
considered  to  be  representative  for  a  population  based  cohort  of  patients  having  highly  specialized  treatment  for
MBDex. As no consecutive list has been kept for patients being treated by internal fixation methods, these patients are
excluded from the COBOM database to eliminate selection bias of long term survivors and as treatment philosophy in
our center is to prefer bone resection and reconstruction, this number is expected to be low.
2.2. Study Population
All  patients  who  contributed  with  data  for  the  current  study  underwent  surgery  for  symptomatic  MBDex.  We
collected information that would have been available prior to surgery from the electronic medical record. Data from
patients who underwent subsequent surgeries during the inclusion period was only included with the first operation in
the  study  period,  thus  not  to  violate  the  assumption  of  independence  [26].  Inclusion  criteria  were:  surgery  due  to
histology-proven  MDB,  with  joint  replacement  surgery  (with  or  without  bone  resection)  or  bone  resection  and
replacement with diaphyseal spacer of a long bone. Exclusion criteria were: surgery in the spine, revision surgery for
failed implants,  other types of surgery such as intramedullary nailing or plate fixation, age under 18 years,  and the
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absence of malignant cells present in resection material. Patients with hematological disease of bone were included in
this study, hence the same surgical treatment approach is used as with metastases caused by solid cancers. Decision-
making for  surgery or  palliative treatment  was based in case-by-case multidisciplinary team evaluation and patient
involvement.
We divided the dataset into two groups, 1 for model development, and 1 for validation based on when electronical
patient files was introduced. The first (training cohort), that consisted of all patients having joint replacement surgery or
a diaphyseal spacer from January 1st 2009 to December 31th 2013 [27], was used to build the prediction models (n =
140). The second (validation cohort), included patients treated from January 1st 2003 to December 31th 2008 (n = 130),
was used to test each model’s performance. Each model was trained to estimate the likelihood of survival (yes/no) at 1,
3, 6 and 12- months after surgery. Due to the Danish Civil Registration System no patients were lost to follow-up [28].
2.3. Prognostic Variables and Dichotomization
Explanatory variables for survival were chosen upon review of the literature and included: primary cancer, grouped
according to Forsberg et al. [29], in brief slow growing cancer with long expected survival (breast, prostate, renal cell,
thyroid cancer, myeloma and lymphoma), moderate growing cancers (sarcoma and other carcinoma) and fast growing
cancers (lung, gastric, hepatocellular and unknown origin). Other included variables were: age at surgery, days from
primary  cancer  diagnosis  to  index  surgery,  presence  of  visceral  metastases,  solitary  or  multiple  bone  metastases,
ischemic heart disease, diabetes, Karnofsky performance score (KPS) [30], The American Society of Anesthesiologists
Physical  Status  classification  system  (ASA-score)  [31],  bone  fracture  or  impending  fracture,  and  preoperative
biochemical  variables  (hemoglobin  level,  neutrophil  count,  C-reactive  protein,  alkaline  phosphatase).  Visceral
metastases were evaluated by preoperative CT scans and considered positive,  if  any dissemination to soft  tissue or
lymph  nodes  were  present  on  scans  performed  within  3  months  prior  to  surgery.  If  no  scans  were  performed,  this
variable was considered missing.
Biochemical variables older than 7 days prior to surgery were also considered as missing variables.
Gender was excluded from the analysis based on its close relation to primary cancer type.
We categorized by reference interval for normal range (neutrophil count) or by interval described in the literature
for survival in patients having surgery for MBDex (KPS). If no consistent scientific evidence for a reference interval
regarding prediction of survival in patients having surgery due to MBDex could be found in the literature, we then
categorized by the median for the combined cohort. This dichotomizing strategy was chosen to minimize confounding
of the data and loss of power.
We categorized KPS ≥ 70 or < 70 (able to work or Eastern Cooperative Oncology Group performance score [32] <1
or >2), ASA score ≤2 or ≥3, hemoglobin ≥ 8 mmol/L (median) or < 8 mmol/L, neutrophil count ≥ 7.9 x109/L (reference
interval)  or  <  7.9  x109/L,  C-reactive  protein  ≥  30  mg/L  (median)  or  <  30  mg/ml,  alkaline  phosphatase  ≥  130  U/L
(median) or < 130 U/L, age ≥ 65 years of age [8] or < 65 years of age, days from diagnose to surgery ≥ 757 (median).
2.4. Development of Prediction Model
Each of  the  above  variables  was  considered  as  candidate  features  for  inclusion  into  the  model.  We produced a
prediction model for survival 1, 3, 6 and 12- months after surgery using a Bayesian Belief Network (BBN) [33] with
patients from the training cohort. The purpose of the 1-month model is to assist the surgeon in decision-making between
pure palliative treatment or surgical treatment. The 3-month model could be used to guide the surgeon between how
durable an implant should be in case of fracture or palliative treatment of an impending fracture. The 6 and 12-month
models  were  produced  to  assist  the  surgeon  in  choosing  a  somewhat  more  durable/invasive  implant  to  ensure  on
surgical implant that will outlive the patient.
We used FasterAnalytics™ v7.0 [34], which employs an unsupervised machine-learning algorithm to calculate joint
probability distributions-how and under what conditions one variable may be represented in terms of other variables-
without defining an a priori hypothesis or designating an outcome variable. All candidate features are considered during
this feature selection process. One of the strengths of using a Bayesian model is its ability to function when some input
data  is  missing.  For  the  end  user,  imputation  of  missing  values  is  unnecessary,  which  makes  it  well-suited  for  the
clinical setting where clinicians are sometimes faced with making decisions with incomplete information.
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2.5. Statistical Analysis
We addressed model performance according to guidelines presented by Steyerberg et al. [35]. Discriminative ability
was described using Receiver Operating Characteristic (ROC) and measurement of Area Under the Curve (AUC) by
producing predictions of survival for each patient in the validation cohort. Decision Curve Analysis (DCA) [29, 36] was
performed to determine what thresholds in the data may be useful for clinical decisions. DCA is a method for evaluating
prediction models in the absence of specific outcome metrics, overcoming a limitation of traditional decision analysis
methods. DCA is utilized to compare prediction models and, importantly, determine whether models are indeed suitable
for clinical use.
Distributions of variables between the two cohorts were tested for equality with non-parametric tests. Continuous
data  with  Mann-Whitney-Wilcoxon  test  and  categorical  data  with  chi-squared  (CHI2)  test.  We used  Kaplan-Meier
estimate  to  compare  overall  survival  between  groups.  Overall  survival  for  these  two  groups  has  previously  been
described by Hovgaard et al. [25]
3. RESULTS
3.1. Comparison of Training and Validation Cohorts
All records contained follow-up sufficient to establish survival at 12 months post-surgery.
Patient demographics can be addressed in Tables 1 and 2. The cohorts contain no differences in age, primary cancer,
fracture,  visceral  metastasis,  solitary  metastasis,  ASA  score  or  KPS  between  the  test  and  validation  cohort  [25].
However, days from the diagnosis of cancer to surgery for MBDex did differ between the two cohorts (p < 0.001) with
a shorter period for the validation cohort.
Table 1. Continuous variables for the training and validation cohort showing statistical differences in distribution between
the two cohorts in Mann-Whitney-Wilcox test except for age and neutrophil count. This did not differ when the variables
where categorized as described.
-
Training cohort
(2009-2013)
n=140
Test cohort
(2003-2008)
n = 130 - -
Variable -
-
Missing
(%)
-
Missing
(%) Mann-Whitney-Wilcoxon test Chi2 test
Age at surgery (years) Mean 64.7 0 63.7 0 0.531 N/A
- Median 65.0 - 64.0 - - -
- Range 21 - 90 - 30 - 85 - - -
Hemoglobin Mean 7.1 0 7.4 1 *0.007 *0.030
(mmol/L) Median 7.1 - 7.5 - - -
- Range 4.8 - 9.8 - 5.0 - 9.7 - - -
C-reactive protein Mean 48.1 - 68.5 15 *0.018 *0.038
(mg/L) Median 21.0 - 37.0 - - -
- Range 1 - 329 4 0 - 266 - - -
Neutrophil count Mean 6.8 16 6.7 32 0.757 1
(x 10^9/L) Median 5.6 - 5.8 - - -
- Range 0.2 - 25.1 - 1.5 - 18.0 - - -
Alkaline phosphase Mean 182.5 16 289.6 9 *0.006 *0.031
(U/L) Median 122.0 - 158.0 - - -
- Range 39.0 - 796.0 - 49.0 - 2520.0 - - -
Days from diagnose
to surgery
Mean 1468 0 1113 0 *<0.001 *0.004
- - - - - - -
(Days) Median 667.6 - 152.5 - - -
- Range 0 - 10610 - 0 -31180 - - -
Due to a high percent of missing values for diabetes and ischemic heart disease, we choose not to perform statistical
test on these variables. Biochemical variables were differently distributed across the cohort for all parameters excluding
neutrophil count (p = 0.757), (Tables 1 and 2).
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Table  2.  Categorized  variables  for  the  training  and  validation  cohort  showing  no  statistical  differences  in  distribution
between the two cohorts in CHI2 test for all variables. Due to a high percentage of missing values for ischemic heart disease
and diabetes in the validation cohort statistical analysis between the cohorts where not performed.
- - Training cohort Validation cohort -
Variable - No. Missing (%) No. Missing (%) Chi2 test
Fracture - - - - - -
- Yes 104 0 94 0 0.819
- No 36 - 36 - -
Cancer group - - - - - -
- Slow 99 0 79 0 0.225
- Moderate 10 - 13 - -
- Fast 31 - 38 - -
Visceral metastases - - - - - -
- Yes 47 0 58 8 0.083
- No 93 - 64 - -
Skeletal metastases - - - - - -
- Solitary 53 0 38 0 0.228
- Multiple 87 - 92 - -
ASA group - - - - - -
- 1 + 2 63 7 74 2 0.147
- 3 + 4 70 - 54 - -
Karnofsky score - - - - - -
- >= 70 96 0 73 3 0.095
- < 70 44 - 53 - -
Ischemic heart disease - - - - - -
- Yes 6 0 0 128 N/A
- No 134 - 2 - -
Diabetes - - - - - -
- Yes 19 0 0 - -
- No 121 - 2 128 N/A
3.2. Bayesian Belief Network Structure
BBNs were produced for all four survival endpoints. The first-degree associates - those variables that were most
influential on 1, 3, 6 and 12-months survival, included: 1 month: KPS, 3 months: KPS, visceral metastasis, alkaline
phosphatase, neutrophil count,  6 months: KPS, alkaline phosphatase, neutrophil count,  hemoglobin and 12 months:
KPS, alkaline phosphatase, neutrophil count, hemoglobin, C-reactive protein and primary cancer group (Figs. 1-4). The
number  of  skeletal  metastases,  diabetes,  bone  fracture  and  age  did  not  add  any  prognostic  information  and  were
excluded as part of the machine learning process.
3.3. Model Performance
Validation showed that our models performed very strongly in predicting survival at 6 and 12 months AUC for the 6
and 12 months models were 81% (C.I.: 74% - 87%) and 84% (C.I.: 77% - 90%), respectively. Discriminatory ability
was fair for the 1 and 3-month models: 68% (C.I.: 55% - 80%), and 69% (C.I.: 60% - 78%), respectively.
On DCA, all four models are suitable for clinical use, and demonstrate positive net benefit, rather than assuming all
patients or no patients survive (Figs. 5-8) 1, 6, or 12 months, respectively. However, with the 3-month model, a surgeon
is better off assuming all patients will survive 1 months if his or her threshold probability for treatment is above 0.58.
Surgeons  typically  have  higher  thresholds  for  treating  sicker  patients,  and  lower  thresholds  for  treating  healthier
patients. Likewise, DCA analysis shows that clinical use of the 1-month model is suitable for treatments thresholds
exceeding 0.72.
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Fig. (1). BBN model for prediction of 1-month survival. ASA: American Society of Anesthesiologist’s score.
Fig. (2). BBN model for prediction of 3-month survival. ASA: American Society of Anesthesiologist’s score.
Fig. (3). BBN model for prediction of 6-month survival. ASA: American Society of Anesthesiologist’s score.
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Fig. (4). BBN model for prediction of 12-month survival. ASA: American Society of Anesthesiologist’s score.
Fig. (5). Decision curves for the 1-month BBN model for survival showing net benefit if using the model at thresholds above 0.72
compared to assuming all patients survive 1- month. MO: Month.
Fig. (6). Decision curves for the 3-month BBN model for survival showing net benefit if using the model at thresholds above 0.52
compared to assuming all patients survive 3- months. MO: Months.
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Fig. (7). Decision curves for the 6-month BBN model for survival showing net benefit at all thresholds compared to assuming all
patients survive 6- months. MO: Months.
Fig. (8). Decision curves for the 12-month BBN model for survival showing net benefit at all thresholds compared to assuming all
patients survive 12- months. MO: Months.
4. DISCUSSION
The treatment of patients with MBDex is dependent, in large part, on each patient’s estimated survival. Herein, we
demonstrate that biochemical variables (C-reactive protein, hemoglobin, neutrophil count and alkaline phosphatase),
can be included into a multivariate model to estimate the likelihood of survival after surgery for MBDex. In addition,
we provide validation data, and decision analysis, which indicates the models may be used in a clinical setting.
4.1. Limitations
Our study is limited by several factors and our results should be interpreted with these in mind; Firstly, data arose
from a single institution although from a prospective maintained database the data is considered retrospective. Secondly
our institution is a tertiary referral center and hereby our population does not truly reflex a population based cohort of
patients  having  surgery  for  MBDex.  This  may  result  in  overfitting  of  the  analysis  in  a  BBN  and  result  in  overly
optimistic results in DCA. As illustrated by the validation of PATHFx [37, 13, 14], it is a problem to find a cohort of
patients having surgical treatment for MBDex with limited missing data. As such, our priority was to use a validation
cohort with a minimum of missing data instead of an independent cohort with large amounts of missing data.
One  may ask  why the  orthopedic  community  needs  additional  prediction  models  when  several  exist?  First,  the
methods we use to estimate survival must be able to accommodate new data, as treatment philosophies change, and
more effective means of treating MBDex become available.  By including biochemical  markers,  we show that  each
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(hemoglobin level, neutrophil count, C-reactive protein, alkaline phosphatase) has predictive value, and may be used as
candidate  features  for  future  generations  of  models.  In  addition,  scoring  systems  developed  from data  collected  of
patients having nonsurgical treatment may impart a time-dependent bias [38], mainly because this treatment generally
occurs prior to the time when the lesion(s) require surgical intervention. Using models developed in this fashion [1, 2,
39], we would tend to overestimate survival and risk over-treating the patients. By only including data available at time
of surgery, we thereby eliminate this bias.
It is important that prognostic models are developed within the context of a defined medical problem, in a specific
patient  population.  Balachandran  et  al.  [40]  underline  the  importance  of  correct  construction,  interpretation  and
application of medical prediction models since they find these incompletely understood by the medical community. By
focusing on patients requiring orthopedic surgical intervention for MBDex, we attempt to overcome this problem by
choosing a cohort that we find is representative of the population.
It is possible that other techniques than BNN may be used to estimate survival. Janssen et al. [8] evaluated three
different methods for development of a prediction model for survival after surgery due to MBDex. In conclusion, they
found that the performance of a boosting algorithm and a nomogram had equal performance. The authors advocated the
use of a nomogram over the boosting algorithm as they find it more easily used in clinical settings. However, the use of
a nomogram forces the clinician to have complete input data, which is not always available in the clinical setting, which
may impart delays in treatment, or limit its use. To mitigate this, Forsberg et al. [29] made a series of Bayesian models
publicly available on www.pathfx.org and made it easily usable in clinical setting.
The choice of a BBN for construction of the prediction model enables us to deal with missing data for the individual
patient without excluding them from analysis. Missing data is a problem in clinical settings specifically in the case of a
fracture where intractable pain of the lesion causes the need for urgent decision-making and leaves little time to further
elucidation if not absolutely indicated.
In the present study, we included biochemical markers that are commonly used in the perioperative setting, but had
not been used in other prediction for survival models. Each has demonstrable prognostic value in estimating survival in
patients with advanced cancer [12, 2, 23, 22, 24, 17 - 21, 41, 15, 11, 7]. In doing so, we produced models with high
discriminatory capacities in an independent cohort, similar to the  internal  validation  statistics  reported by  Janssen et
al. [8] as  well as  the  external  validation of  PATHFX by  Forsberg et al.  [18], Piciolli et al.  [13] and Ogura et al.
[37]. This is an important observation, since models exhibit a decrease in discriminative ability when presented with
unknown records during external validation. As such, models that have not undergone external validation in an intended
patient population are not recommended for clinical use.
To our knowledge, no other models other than Janssen and PATHFx for prediction of survival in patients having
surgery for MBDex have been externally validated. None of the mentioned models includes C-reactive protein, which
has shown to be a strong predictor for survival in patients with cancer [16, 15] nor alkaline phosphatase [17, 19 - 21].
No studies have addressed the connection between survival in patients having surgery due to MBDex and neutrophil
count, however, Forsberg et al. [42] included absolute lymphocyte count (off which neutrophil count is a subset) in the
PATHFX model. Literature underline that neutrophil count is associated with survival in cancer patients with metastatic
bone disease [21 - 24] and this is coherent with findings in this study. Biochemical variables are objective variables
opposed to KPS, ASA-score etc. A non-objective variable is dependent on the observer’s qualification and can therefore
bias  the  outcome  of  a  prediction  model  for  the  individual  patient.  By  including  more  objective  variables,  such  as
biochemical  variables,  we  believe  that  our  model  becomes  more  robust  and  less  observer  dependent  and  thus
minimizing  observation  bias  in  our  model.
The clinical rationale for development of prediction models for survival in patients having surgery for MBDex is to
produce a tool that can guide the surgeon into choosing the right treatment for the individual patient, so the patient only
need one operation and can avoid revision surgery. We choose to develop the 1-month model to assist the surgeon or
the medical oncologist in choosing between surgery or palliative treatment. Prediction horizons of 3-, 6- and 12 months
was produced to assist the surgeon in choosing between a more or less durable implant (internal fixation versus joint
replacement), as it has been shown that the use of intern fixation in long term survivors will result in revision due to
implant failure [43, 44] as one cannot expect a metastatic lesion to heal, not even under radiation therapy [45]. Even
though a recent review [46] of musculoskeletal tumor surgeons has shown that survival predictions of 6 months after
surgery is of interest for choosing between various surgical treatment modalities for the proximal femur, the authors feel
that the clinical reality is not always as straight forward, and the need for prediction of shorter (3 months) or longer
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(twelve  months)  survival  is  of  interest  in  case  of  pending  surgical  treatment  for  metastatic  lesions  also  in  other
anatomical regions than the proximal femur and was thus included into our prediction model.
We choose to evaluate the usefulness of the models by DCA. DCA is about evaluating the net benefit of using a
model compared to assuming all patients either survive or dies at different thresholds for individual survival predicted
by a given model. In clinical settings, a surgeon might require a high probability of survival before offering a costly
procedure to a patient with a high risk of perioperative/postoperative complication. If this survival probability is lower
than the threshold probability for the given model in a DCA analysis the surgeon is better off not using the model at all.
DCA analysis of the 1-month model suggests using the model rather than assuming a patient will survive/die if we
demand a 72% or higher probability of surviving one month.
Interestingly  the  3-month  model  yields  negative  net  benefit  at  threshold  below  0.52  compared  to  the  clinician
expecting all to survive and it is therefore not recommended to use the model at lower thresholds. Piccioli et al. [13]
observed similar findings in DCA analysis of the PATHFX 3-month model although they found a threshold at 0.90,
which is increased to our findings (0.52). Ogura et al. [37] observed something similar for their 1 month (0.80) and 3-
month prediction model (0.60). This large difference of net benefit across threshold probabilities can be explained by
our two cohorts being very homogeneous (most variables have the same distribution in the training and the validation
cohorts and no significant difference in survival pattern was observed) in contrast to the training and various validation
cohorts of the PATHFx.
The authors underline that the result of this study is only applicable for patients whom is designated to undergo
surgery for MBDex and not for those where non-surgical interventions is the clinician first choice of treatment for a
metastatic lesion, and a recently published study documented that one could expect approximately below 80% of the
patients admitted to an orthopedic department suffering from MBDex will be treated surgically [47].
CONCLUSION
In conclusion, we generated prediction models designed to estimate the likelihood of survival at four useful time-
points also including common biochemical markers together with primary cancer type, presence of visceral metastasis,
KPS, ASA group, ischemic heart disease, days from diagnosis of cancer to surgery for MBDex; we ensured each model
was suitable for clinical use using decision analysis. These models may now be used to assist the surgeon or the medical
oncologist in their clinical decision making when treating MBDex.
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